Malaysia HIV Therapeutics Market Analysis Report [2022-30]

Malaysia HIV Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Malaysia HIV therapeutics market will reach a value of $xx Mn from $22.12 Mn in 2022, growing at a CAGR of xx% during 2022-2030. The market is primarily dominated by local players such as HVC Medical Supplies, KLSCAH, and Pharmaniaga Berhad. The market is driven by the prevalence of HIV infections and inequalities in the treatment of HIV. The HIV therapeutics market in Malaysia is segmented by type, product, and geography, end user, and distribution channel.

ID: IN10MYPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Malaysia AUTHOR: Dr. Vishwa Modhia

Buy Now

Malaysia HIV Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Malaysia HIV therapeutics market will reach a value of $xx Mn from $22.12 Mn in 2022, growing at a CAGR of xx% during 2022-2030.

Malaysia, a Southeast Asian country, is a federation of 13 states and 3 federal territories. The most recent WHO statistics from 2020 show that 2,679 people died in Malaysia from HIV/AIDS or 1.59% of all deaths. The United Nations reports that Malaysia is one of the ten nations that, collectively, accounted for more than 95% of all new HIV infections in the Asia-Pacific region in 2016.

In September 2018, "HIV Connect,” a self-paced, online learning platform that is designed for primary care physicians and other healthcare practitioners in Malaysia, was launched. With an age-adjusted death rate of 8.15 per 100,000 people, Malaysia is ranked 63rd globally. With a 0.3% prevalence rate, Malaysia was ranked 81st in the world for adult HIV/AIDS prevalence in 2021. 9.7% of Malaysia's GDP was spent on healthcare expenses in that year.

Malaysia HIV therapeutics market analysis

Market Dynamics

Market Growth Drivers

Over the past 20 years, Malaysia has seen a 70% decrease in the number of new HIV infections. People living with HIV (PLHIV) in Malaysia were receiving antiretroviral treatment at a rate of 66% in 2021, as opposed to 28% in 2015. For the nation to completely eradicate AIDS as a public health problem by 2030, the decline in HIV cases and the expansion of treatment access are still insufficient.

Market Restraints

The effort to cover the entire region of Malaysia is hampered by inequalities. Therefore, it is essential to improve the accessibility, value, and suitability of services for HIV treatment, testing, and prevention in order to ensure that equality is achieved. This disparity may deter new competitors from the HIV therapeutics market in Malaysia.

Competitive Landscape

Key Players

Pharmaniaga Berhad (MYS)
KLSCAH (MYS)
HVC Medical Supplies (MYS)
Gilead Sciences
Pfizer
AstraZeneca
Novartis
GlaxoSmithKline

Healthcare Regulations and Reimbursement Policies

The regulatory body in charge of approving and supervising HIV therapeutics in Malaysia is the National Pharmaceutical Regulatory Agency (NPRA), a division of the Ministry of Health. The NPRA is responsible for ensuring the safety, efficacy, and quality of all drugs, including those used to treat HIV. Prior to being marketed and sold in Malaysia, the NPRA assesses new medications, including HIV therapeutics.

In Malaysia, the National Health Insurance Scheme (NHIS), also referred to as "MyKasih," pays for HIV therapeutics. A variety of medical treatments, including the price of HIV medications, are covered by the government-run health insurance program known as the National Health Insurance System (NHIS). Depending on the person's plan and the medication being taken, the NHIS covers HIV therapeutics to varying degrees.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.